Literature DB >> 25750109

Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.

Hironori Ishibashi1, Masashi Kobayashi, Chihiro Takasaki, Kenichi Okubo.   

Abstract

OBJECTIVE: Surgical procedure for malignant pleural mesothelioma (MPM) remains controversial. We reviewed our protocol including pleurectomy/decortication (P/D) for patients with malignant pleural mesothelioma who were intolerable to extrapleural pneumonectomy (EPP). PATIENTS AND METHODS: From June 2010 to April 2014, 14 patients with MPM were intended to treat with multimodality therapy including surgery. Four patients who were intolerable to EPP received a protocol consisting of P/D and intraoperative intrapleural hyperthermic cisplatin perfusion, followed by systemic chemotherapy. Ten patients received trimodality treatment of EPP, systemic chemotherapy, and intensity modulated radiation therapy for hemithorax. Surgical outcomes of acute operative results and interim survivals were examined and compared between the groups.
RESULTS: All patients obtained macroscopic complete resection and received multimodality treatment in P/D and EPP groups. Operation time was longer in P/D group; however, there were no differences in ICU stays or hospitalizations. Four patients in P/D group and seven patients in EPP group experienced postoperative complications; however, there was no operative morality. EPP group suffered from cardiac complications and P/D group had prolonged airleak. Full walk recovery was obtained earlier in P/D group. One patient in P/D group had a local recurrence 11 months after surgery, while the other three patients survived 23-41 months with no evidence of diseases.
CONCLUSIONS: P/D and intraoperative intrapleural cisplatin perfusion achieved a favorable macroscopic resection in patients with MPM who were intolerable to EPP. Postoperative complications were manageable and survival could be promising. Further study warrants with a larger number of patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25750109     DOI: 10.1007/s11748-015-0535-x

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  28 in total

1.  Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.

Authors:  Loïc Lang-Lazdunski; Andrea Bille; Rohit Lal; Paul Cane; Emma McLean; David Landau; Jeremy Steele; James Spicer
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

3.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

4.  Trimodality management of malignant pleural mesothelioma.

Authors:  G Maggi; C Casadio; R Cianci; O Rena; E Ruffini
Journal:  Eur J Cardiothorac Surg       Date:  2001-03       Impact factor: 4.191

5.  Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg; Melissa J Culligan; Rosemarie Mick; James Stevenson; Stephen M Hahn; Daniel Sterman; Salman Punekar; Eli Glatstein; Keith Cengel
Journal:  Ann Thorac Surg       Date:  2012-05       Impact factor: 4.330

6.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors:  V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

7.  The management of malignant pleural mesothelioma; single centre experience in 10 years.

Authors:  Tarek Aziz; Ali Jilaihawi; Dhruva Prakash
Journal:  Eur J Cardiothorac Surg       Date:  2002-08       Impact factor: 4.191

8.  Trimodality therapy for malignant pleural mesothelioma.

Authors:  Gordon Buduhan; Shekhar Menon; Ralph Aye; Brian Louie; Vivek Mehta; Eric Vallières
Journal:  Ann Thorac Surg       Date:  2009-09       Impact factor: 4.330

9.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

10.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

View more
  8 in total

1.  Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS.

Authors:  Runlei Hu; Hong Jiang; Hu Li; Dongshan Wei; Guoqing Wang; Shenglin Ma
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 2.  The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.

Authors:  Pietro Bertoglio; Vittorio Aprile; Marcello Carlo Ambrogi; Alfredo Mussi; Marco Lucchi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 3.  Current surgical strategies for malignant pleural mesothelioma.

Authors:  Teruhisa Takuwa; Seiki Hasegawa
Journal:  Surg Today       Date:  2015-11-21       Impact factor: 2.549

4.  Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.

Authors:  Masashi Kobayashi; Hironori Ishibashi; Chihiro Takasaki; Sachiko Imai; Susumu Kirimura; Kenichi Okubo
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

Review 5.  Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies.

Authors:  Till Markowiak; Christopher Larisch; Hans-Stefan Hofmann; Michael Ried
Journal:  Ann Transl Med       Date:  2021-06

Review 6.  Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis.

Authors:  Hua Zhou; Wei Wu; Xiaoping Tang; Jianying Zhou; Yihong Shen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.

Authors:  Zi-Yi Zhao; Sha-Sha Zhao; Meng Ren; Zi-Ling Liu; Zhi Li; Lei Yang
Journal:  Oncotarget       Date:  2017-10-19

8.  Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany.

Authors:  Till Markowiak; Michael Koller; Florian Zeman; Gunnar Huppertz; Hans-Stefan Hofmann; Michael Ried
Journal:  BMJ Open       Date:  2020-07-20       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.